Ranbaxy
-
Ranbaxy and Pfēnex Announce Collaboration for Biosimilar Therapeutic Protein Development
Ranbaxy will develop an undisclosed biosimilar therapeutic that is produced in the PfÄ“nex Expression Technology platform, a Pseudomonas-based recombinant protein expression technology. Under the terms of the agreement, PfÄ“nex is eligible to rec…
Ranbaxy | 08 April 2010
-
Daiichi Sankyo to Expand Business Scope in Japan
Daiichi Sankyo and Ranbaxy Laboratories have announced that the former will establish Daiichi Sankyo Espha Co on April 1, 2010. The new company will market generic drugs, as well as the former’s products. Completing their strategic alliance in…
Ranbaxy | 05 March 2010
-
Daiichi Sankyo and Ranbaxy to Launch Products in Mexico
Daiichi Sankyo and Ranbaxy Laboratories have announced plans to introduce innovator products of the former in Mexico through the marketing division that was created last year within latter’s Mexican subsidiary, Ranbaxy Mexico. The companies ha…
Ranbaxy | 19 February 2010
-
Ranbaxy Acquires Product Rights from Biovel in India
Ranbaxy Laboratories has announced the signing of agreements with Biovel Lifesciences, Bangalore, India, providing for the acquisition of product rights and a manufacturing facility, from the latter. The proposed transaction will give the former…
Ranbaxy | 05 February 2010
-
Ranbaxy Launches NCE for Indian Dermatology market.
Ranbaxy Laboratories has launched a New Chemical Entity (NCE), Lulifin (Luliconazole), in the Indian Dermatology market. This follows a strategic in-licensing agreement with Summit Pharmaceuticals International Corporation, Japan (SPI) allowing t…
Ranbaxy | 27 January 2010
-
Ranbaxy to Transfer Stake in China to HNG Chembio Pharmacy
Ranbaxy Laboratories and HNG Chembio Pharmacy have announced the transfer of the former's entire shareholding in Ranbaxy (Guangzhou China) Limited (RGCL) to HNG Chembio Pharmacy Co (HNG). This transaction is part of the former’s endeavour to dev…
Ranbaxy | 20 January 2010
-
Daiichi Sankyo and Ranbaxy Launch Antihypertensive Drug in Africa
Ranbaxy will launch Olmesartan Medoxomil, an antihypertensive that was originally discovered by Daiichi Sankyo, in six African countries. The countries are Kenya, Mozambique, Nigeria, Tanzania, Uganda, and Zambia. The companies will launch the produc…
Ranbaxy | 14 January 2010
-
CIP-Isotretinoin to be Distributed in the US
Cipher has granted Ranbaxy Pharmaceuticals Inc. (RPI) the exclusive right to market, sell and distribute CIP-Isotretinoin in the US. CIP-Isotretinoin is a patented formulation of isotretinoin, which is used in the treatment of severe nodular acne. T…
Ranbaxy | 01 September 2008
-
Ranbaxy launches business operation in Yemen
Ranbaxy Laboratories Limited has started its operation in Yemen, introducing its products to around 350 doctors. Ranbaxy tied up with Pharma Ltd (Natco) as business partners for its Yemen operations. Pharma Ltd is one of the pioneers in the H…
Ranbaxy | 26 May 2008
-
Ranbaxy Receives Tentative Approval To Manufacture And Market Esomeprazole Magnesium Dr Capsules In US
Ranbaxy Laboratories Limited (RLL) said the company has received tentative approval from the US Food and Drug Administration for Esomeprazole Magnesium Delayed-Release Capsules, 20 mg (base) and 40 mg (base). Nexium (Esomeprazole) is the second large…
Ranbaxy | 20 February 2008
